Abstract
Results
IHC showed that the rates of expression of the signal transduction molecules mTOR, pmTOR, p70S6k and p-p70S6K in GC were 60.8%, 54.2%, 53.3% and 53.3%, respectively. Overexpression of mTOR and p70S6K showed no significant association with clinical variables. Expression of p-mTOR was significantly associated with differentiation (P < 0.01), depth of invasion (P < 0.01), lymph node metastasis (P = 0.04) and TNM stage (P = 0.02). Expression of p-p70S6K was associated with differentiation (P = 0.006), depth of invasion (P < 0.001), and TNM stage (P = 0.02). In survival analysis, differentiation, depth of invasion, lymph node metastasis and TNM stage were not related to OS (all P > 0.05). Furthermore, p-mTOR and p-p70S6K expression, but not mTOR and p70S6K, were tightly associated with OS of GC patients (P = 0.006 and P < 0.001, respectively). In Western blot, p-mTOR was significantly higher in GC tissues than in normal and adjacent tissues. In the present a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Immunohistochemistry
The tissue samples were fixed in 10% neutral formalin and embedded in paraffin for sectioning and staining according to the manufacturer's instructions. The 3-to 5-μm-thick tissue sections were deparaffinized and hydrated in xylene and serially diluted ethanol, respectively. The endogenous peroxidase was blocked by incubation with 3% H 2 O 2 for 10 min. Antigen retrieval was performed in a microwave oven using citrate solution. Subsequently, the tissue sections were incubated with the appropriate primary antibody for 12 h to 16 h at 4˚C. The slides were washed three times in phosphate-buffered saline (PBS) and incubated with secondary antibody for 20 min. After three further washes in PBS, diaminobenzidine tetrahydrochloride (DAB) was used before counter staining with hematoxylin. The following primary antibodies were used: mTOR (1:150), p-mTOR (1:200) (Abcam, Cambridge, UK), p70S6K (1:150) (Abcam, Cambridge, UK) and p-p70S6K (1:100) (Elabscience, Wuhan, China).
Evaluation of immunohistochemistry
The results of immunohistochemical staining for mTOR and p-mTOR were evaluated by two independent investigators according to a semiquantitative grading system based on the proportion of stained cells and their intensity [14] . The results of immunohistochemical staining were also evaluated under similar scoring criteria. Staining intensity was scored as: 0 (negative), 1 (weak), 2 (moderate), or 3 (strong). The percentage of positive epithelial cells was scored as: 0 (no staining), 1(<1/3 staining), 2 (1/3 to 2/3 staining), and 3 (>2/3 staining). A histological score was generated as the product of intensity and the percentage of positive epithelial cells. The results of immunostaining were divided into two groups, with 0-2 score regarded as negative and >2 score considered as positive expression.
Protein extraction and Western blot
Total protein was extracted from the normal mucosa, para-carcinoma and corresponding tumor tissues of 10 GC patients using RIPA lysis buffer (Beyotime, Shanghai, China). The protein concentration was quantified using the Enhanced BCA Protein Assay Kit. The equivalent proteins in each pair of specimens were separated by SDS-PAGE on 12% polyacrylamide gels and electrotransferred to polyvinylidene fluoride membranes. After blocking in TBST (Trisbuffered saline/Tween-20 buffer) containing 5% skim milk for 1 h at room temperature, the membrane was incubated in TBST solution containing anti-p-mTOR (1: 2000, Abcam, Cambridge, UK) overnight at 4˚C. After washing three times in TBST, the membranes were incubated with the corresponding secondary antibodies in TBST along with 3% skim milk powder for 1 h at room temperature. After three washing steps in TBST, the band intensity was measured using the BandScan software. The p-mTOR band intensities were normalized to GAPDH signals.
Statistical analysis
Statistical analyses were performed using the SPSS version 16.0 (SPSS Inc., Chicago, IL, USA). Associations between variables were examined using Pearson's chi-squareand, Continuity correction Fisher's exact tests. Survival curves were calculated by the Kaplan-Meier method, and the statistical significance was evaluated using the log-rank test. Results were considered statistically significant if P<0.05.
Meta-Analysis Aims
Because of a small number of patients, a meta-analysis was conducted to confirm the previous results of IHC and survival analysis, and fully investigate whether exist relationship between mTOR, p-mTOR and clinicopathological parameters, OS through meta-analysis.
Methods
Relevant articles were searched from PubMed, Ovid, Web of Science, and Cochrane from Feb 2002 to Jul 2016. The search terms used were: ("mTOR" OR "the mammmalian target of Rapamycin" OR "p-mTOR" OR "phosphrylated mTOR" OR "phosphorylated mammmalian target of Rapamycin") AND ("gastric" OR "stomach" OR "cardia" OR "gastrointestinal") AND ("adenocarcinoma" OR "carcinoma" OR "cancer" OR "tumour" OR "neoplasm" OR "tumor"). The full texts of the studies were reviewed to determine eligibility based on the inclusion criteria (Fig 1) .
The full texts of the studies were read and selected if they met the following inclusion criteria: (1) GC was identified, (2) expression of proteins was evaluated by IHC, (3) clinicopathological parameters and OS were available, (4) standards to assess the protein expression was consistent across different studies, and (5) the article was published in English and Chinese. Two investigators (Guo-dong Cao and Xing-yu Xu) extracted the data independently based on consensus. The following data were extracted: first author's name, year of publication, total number of patients, clinicopathological parameters, and survival time. During the data extraction, any disagreements were resolved by a third investigator (Bo Chen) and a consensus was reached. Two investigators (Guo-dong Cao and Xing-yu Xu) assessed the quality of included studies using the Newcastle-Ottawa scale [15] .
All the statistical analyses were performed using the STATA software (version 11.0, StataCorp LP, College Station, TX, USA). The crude odds ratio (OR) and 95% confidence interval (CI) were used to estimate the strength of the association between mTOR, p-mTOR and clinicopathological parameters of GC patients. Risk ratios (RR) and 95% CIs were used in this meta-analysis to estimate the association of the status of pathway-related proteins with OS. I 2 value, which indicated the percentage of total variation across studies, was used to assess statistical heterogeneity. Random-effects models (I 2 >50% or P < 0.1) of analysis were used if significant heterogeneity was detected. Otherwise, fixed-effects models were used. Begg's rank correlation and Egger's weighted regression methods were used to determine potential publication bias (P < 0.05 indicates statistically significant publication bias).
Results

Expression of mTOR, p-mTOR, p70S6k and p-p70S6K in GC
The IHC images were demonstrated in Figure 2a (Fig 2a) . According to the IHC results, mTOR and p-mTOR were highly expressed in GC tissue ( Table 1 ). The overall rate of mTOR overexpression in 120 GC patients was 60.8%, and the overall rate of p-mTOR overexpression in 120 GC patients was 54.2%. IHC showed that the concurrent rate of p70S6k and p-p70S6K expression in GC was 53.3%. No significant difference was found between this study and previous studies (Table 2 ). In addition, according to Spearman correlation analysis, mTOR and pmTOR were both significantly linked to p-p70S6K expression (P = 0.002 and P < 0.001, respectively, Table 3 ). As one of the major downstream proteins of PI3K/Akt/mTOR pathway, the activation of mTOR was detected in 10 paired GC samples including adjacent and normal tissues by Western blot. The p-mTOR expression was significantly higher in GC tissues indicating that it was probably related to GC tumorigenesis (Fig 2b) .
Association between mTOR, p-mTOR, p70S6k, and p-p70S6K expression and relevant parameters As shown in Tables 1 and 2 , the overexpression of mTOR was not significantly associated with sex, tumor size, differentiation, and tumor location, depth of invasion, and lymph node metastasis, or distant metastasis. However, mTOR expression was significant correlated with TNM stage (P = 0.03). The p70S6K expression showed no significant association with any other clinical parameters, except depth of invasion (P = 0.03). Meanwhile, in the present study, p-mTOR was significantly linked to differentiation (P < 0.01), depth of invasion (P < 0.01), lymph node metastasis (P = 0.04) and TNM stage (P = 0.02). The p-p70S6K expression was associated with differentiation (P = 0.006), depth of invasion (P < 0.001), and TNM stage (P = 0.02). The positive expression of p-mTOR and p-p70S6K suggested the possibility of poor differentiation, deeper invasion, positive lymph node metastasis and delayed TNM stage.
Survival analysis
Survival analysis was demonstrated in Fig 2. OS was not related to differentiation (Log-Rank test: P = 0.38, Fig 3a) , depth of invasion (Log-Rank test: P = 0.20, Fig 3b) , lymph node . GC patients with p-mTOR overexpression showed significantly shorter overall survival rates than p-mTOR negative GC patients (Log-Rank test: P = 0.006) (Fig 3f) . Further, p-p70S6K expression was significantly associated with OS of GC patients (Log-Rank test: P < 0.001) (Fig 3g) . However, no such association was found between OS and p70S6K (Log-Rank test: P = 0.28) (Fig 3h) .
Univariate and multivariate analysis of OS
The prognostic relevance of mTOR, p-mTOR and several clinical factors was evaluated using univariate and multivariate analysis, respectively. In univariate analysis, none of the clinical factors or mTOR was associated with OS, except for p-mTOR (Hazard ratio = 1.88, 95% CI: 1.19-2.99, P = 0.01, Table 4 ) and p-p70S6K (Hazard ratio = 2.64, 95% CI: 1.65-4.23, P < 0.001, Table 2 ). The multivariate Cox proportional hazards model showed a significant correlation between p-p70S6K expression and OS (Hazard ratio = 3.00, 95% CI: 1.45-6.20, P = 0.003, Table 2 ).
Study characteristics of meta-analysis
After reviewing the abstracts and full texts, three studies of mTOR [16] [17] [18] and seven studies involving p-mTOR [11, [18] [19] [20] [21] [22] [23] overexpression in GC met the inclusion criteria and were selected, respectively (Fig 3) . The characteristics of the eligible studies are listed in Table 5 . The study samples were analyzed using IHC and the standards for assessment were almost consistent. The mTOR positive expression in the eligible studies ranged from 51.5% to 54.6%, and the total rate of mTOR overexpression in GC patients of all the studies was 53.9% (817/1517). The rate of p-mTOR overexpression in GC ranged from 31.6% to 74.0%, and the overall rate was 48.3% (1387/2874). Correlation of mTOR and p-mTOR with clinicopathological parameters
As shown in Table 6 , no correlation was found between mTOR overexpression and any clinicopathological parameters, such as differentiation (OR = Fig 4b) . The p-mTOR overexpression was independent of sex, age, differentiation, lymph node metastasis, and distant metastasis suggesting that p-mTOR was involved in tumor progression.
Correlation of mTOR and p-mTOR overexpression with OS
The survival time was extracted from the Kaplan-Meier survival curves analyzed by Enguage Digitizer software. In the present study, mTOR-positive expression was not correlated with the 1-, 3-and 5-year overall survival rate of the GC patients (Table 7) . However, p-mTOR expression was significantly related to 1-(RR = 1.86, 95%CI: 1.50-2.31, P < 0.001 , Fig 5a) 
Sensitivity analysis and publication bias
In order to test the robustness of the RR estimates of OS, sensitivity analysis was conducted by individually excluding the studies and analyzing the effects on the remaining studies. As shown in Fig 6, the results of RR estimates were relatively reliable and credible as no point estimate of the omitted individual study was outside the 95% CI.
Begg's rank correlation and Egger's weighted regression methods were used to statistically assess the publication bias. As shown in Fig 7a and 7b , neither Begg's (P = 0.23) nor Egger's (P = 0.70) test provided any clear evidence of publication bias. These results indicate the absence of publication bias in the current study. We believe that the results of our meta-analysis are credible. 
Discussion
The prognostic role of mTOR and p-mTOR expression has been studied extensively in other types of cancers, despite controversial results. Li et al. [24] first investigated the prognostic value of mTOR and p-mTOR in non-small cell lung (NSCLC) cancer comprehensively in a meta-analysis. In this study, no statistically significant association was found between mTOR and p-mTOR expression, and prognosis of NSCLC patients. The mTOR is a down-stream effector of PI3K-Akt signaling pathway and is regarded as a Ser/Thr protein kinase that mediates nutrient-dependent intracellular signaling related to cell growth, proliferation, and differentiation. Previous studies have identified mTOR signaling as a potential target for anticancer therapy using several cancer models [25] . Furthermore, the mTOR is activated and phosphorylated (p-mTOR). Osaki et al. [26] reported that p-mTOR is frequently expressed in ovarian cancer and may be targeted to disrupt ovarian tumor cell growth. Association between mTOR and p-mTOR expression, and GC remains unclear. The role of mTOR and p-mTOR as prognostic predictors is controversial and warrants further investigation. Interestingly, our original study demonstrated that both mTOR and p-mTOR were associated with several clinicopathological parameters such as TNM stage (P < 0.05). However, in the survival analysis, p-mTOR overexpression was significantly related to overall survival of GC patients (P = 0.006). No obvious difference was found between mTOR overexpression and OS in GC.
These inconsistent but interesting results require comprehensive investigation. Concurrently, because of limitations associated with small sample size, the meta-analysis was conducted to determine the prognostic value of mTOR and p-mTOR. Finally, in this metaanalysis, mTOR was not correlated with clinicopathological variables or OS. However, the correlation was found between depth of invasion and TNM stage, which are tumor predictors. Nonetheless, p-mTOR overexpression always indicates a shorter survival time in GC.
The mTOR has two main downstream factors, eukaryotic initiation factor 4E binding protein 1(4E-BP1) and ribosomal S6 kinase (p70S6K), which were mediated by phosphorylated mTOR activity [27] . Dephosphorylated 4E-BP1 binds to eukaryotic initiation factor 4E (eIF-4E), leading to inhibition of translation initiation. Phosphorylation of 4E-BP1 by pmTOR releases 4E-BP1 from the mRNA cap-binding protein eIF4E, triggering the process of translation and protein synthesis [28, 29] . The p-mTOR activates p70S6K, and phosphorylated p70S6K combines with translation initiation complexes, to improve the efficiency of mRNA translation [30] . In general, p-mTOR induces phosphorylation of 4E-BP1 and P70S6K, and initiation of translation and protein synthesis. Yu et al. [18] reported that p-mTOR overexpression was related to clinicopathological variables and p-mTOR appears to be a more sensitive biomarker than total mTOR in predicting patient survival. Ji et al. [31] reported that targeting the expression of p-mTOR with specific siRNA reduced the growth and overall survival rate of Hela cervical cancer cells in vitro. The process of mTOR phosphorylation is suppressed by mTOR-specific inhibitors, such as everolimus and rapamycin. Phase II studies showed that treatment strategies using everolimus showed high efficacy and safety in GC, and therefore a global phase III study is currently underway [32] . Riquelme et al. [33] found that rapamycin treatment did not significantly alter the protein expression of total mTOR in several types of cell lines. However, rapamycin significantly decreased the phosphorylation of both mTOR and its downstream effectors, such as p70S6K1 and 4E-BP1. In a previous study [34] , Yang and his co-workers used Western blot and reverse transcription polymerase chain reaction (RT-PCR) to assess the expression of mTOR in GC. The findings suggest that the expression of mTOR at the protein level was significantly lower than in the corresponding normal gastric mucosa, while the ratio of p-mTOR was significantly increased in tumor tissues. The conclusion was that the mTOR signaling pathway was activated in GC, mainly via increased mTOR phosphorylation rather than overexpression of dephosphorylated mTOR. In our original survival analysis, the results indicated that p-mTOR overexpression was significantly associated with overall survival rate. However, the mTOR expression and TNM stage were meaningless. Furthermore, in this meta-analysis, we arrived at a similar conclusion suggesting that p-mTOR plays a key role in GC as a promising predictor.
However, the limitations of the current study include: (1) small number of patients; (2) exclusion of a few eligible non-English and non-Chinese studies; and (3) insufficient number of articles. However, several advantages were as follows: (1) This is the first available study and meta-analysis of the association between mTOR, p-mTOR overexpression and clinicopathological parameters in GC. (2) We also compared the prognostic value of mTOR and p-mTOR in GC for the first time. (3) The results of this study provide theoretical support of rapamycin treatment in GC.
In summary, it is not possible to accurately predict the prognosis of GC patients on the basis of the current staging system alone. The expression of p-mTOR is significantly associated with clinicopathological parameters and OS, and plays a vital role in the progression of GC. It is a more valuable prognostic factor than mTOR in GC and may be regarded as a new predictor. 
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